Successful alectinib treatment after crizotinib‐induced interstitial lung disease

A 70‐year‐old woman with lung adenocarcinoma, harbouring anaplastic lymphoma kinase gene rearrangement, was treated with crizotinib as third‐line chemotherapy. After 2 months, crizotinib was discontinued because of the development of crizotinib‐induced interstitial lung disease (ILD). Steroid treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujiuchi, Satoru, Fujita, Yuka, Sasaki, Takaaki, Ohsaki, Yoshinobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4968663/
https://www.ncbi.nlm.nih.gov/pubmed/27516885
http://dx.doi.org/10.1002/rcr2.156

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4968663/
https://www.ncbi.nlm.nih.gov/pubmed/27516885
http://dx.doi.org/10.1002/rcr2.156

Ejemplares similares